# Niagen Bioscience, Inc. Common Stock (NAGE)

> Niagen Bioscience, Inc. Common Stock (NAGE) trades at $2.04 (+1.49%) as of 6:54:53 PM EST on Nov 17, 2026, -18.40% over the past month. Market cap is $159.19M, with 8.9 days to cover in short interest.

Canonical: https://massive.com/quote/nage
Data as of: 2026-11-17T23:54:53.455Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$2.04** +0.03 (+1.49%)
As of 6:54:53 PM EST on Nov 17, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Niagen Bioscience, Inc. Common Stock (NAGE) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +1.49% |
| 1W | -5.12% |
| 1M | -18.40% |
| YTD | -67.92% |
| 1Y | -70.26% |
| 52-wk range | $1.95 – $7.12 |

From daily closes through Nov 17, 2026.

## Key statistics

Today's trading snapshot for NAGE: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $1.95 – $2.05 |
| Open | $2.00 |
| Prev close | $2.01 |
| Volume | 1.03M |
| Market cap | $159.19M |
| Shares out | 79.2M |

## Valuation and profitability ratios

Valuation and profitability ratios for Niagen Bioscience, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 15.55 |
| P/S | 1.30 |
| P/B | 1.92 |
| P/FCF | 34.76 |
| ROE | 12.3% |
| ROA | 9.4% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 16, 2026

## Insider trading

[Niagen Bioscience, Inc. Common Stock (NAGE) insider trading](https://massive.com/quote/nage/insider-trading.md): open-market Form 4 buys and sells by Niagen Bioscience, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Niagen Bioscience, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 4, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 4, 2026, Niagen Bioscience, Inc. (the "Company") issued a press release announcing its earnings for the quarter ended September 30, 2026.”
- Aug 4, 2026 · Investor presentation
  “On August 4, 2026, the Company released a corporate presentation which it made available on its website.”
- Jun 29, 2026 · Annual meeting results
  “Set forth below are the results of the matters submitted for a vote of stockholders at the Company's 2026 Annual Meeting. Proposal 1 — Election of directors. The following directors were elected to serve until the Company's 2027 Annual Meeting of Stockholders...”
- May 6, 2026 · Investor presentation
  “On May 6, 2026, the Company released a corporate presentation which it made available on its website.”
- Mar 19, 2026 · [Share repurchase program](https://massive.com/quote/sec-filings/8-k/share-buybacks.md)
  “the Board of Directors (the "Board") of Niagen Bioscience, Inc. (the "Company") approved an increase in the authorization under the Company's share repurchase program. Under the amended authorization, the Company may repurchase up to $20.0 million of its outstanding common stock, representing an increase from the previously authorized $10.0 million share repurchase program approved by the Board on October 31, 2025.”

## Dividend history and stock splits

Niagen Bioscience, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 3.1887751-for-1 · Dec 7, 2006

## NAGE short interest

How heavily NAGE is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.9 |
| Short interest | 4.35M |
| Avg volume | 487.93K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## NAGE news

The latest news and headlines about Niagen Bioscience, Inc. Common Stock (NAGE).

- [Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue Estimates](https://www.zacks.com/stock/news/3023639/niagen-bioscience-nage-reports-q3-loss-lags-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3023639) · Zacks Investment Research · Nov 4, 2026 · negative sentiment
- [Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know](https://www.zacks.com/stock/news/3020664/will-coherus-oncology-chrs-report-negative-earnings-next-week-what-you-should-know?cid=CS-ZC-FT-fundamental_analysis|yseop_template_9-3020664) · Zacks Investment Research · Nov 2, 2026 · negative sentiment
- [Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline](https://www.zacks.com/stock/news/3017281/earnings-preview-niagen-bioscience-nage-q3-earnings-expected-to-decline?cid=CS-ZC-FT-fundamental_analysis|yseop_template_9-3017281) · Zacks Investment Research · Oct 28, 2026 · negative sentiment
- [Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED)](https://www.benzinga.com/markets/earnings/26/03/51050507/niagen-bioscience-doubles-annual-profit-ceo-signals-acquisition-hunt-and-glp-1-style-expansion?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Mar 5, 2026 · positive sentiment
- [National Advertising Division Finds Certain Reus Cata-Kor NAD+ Claims Supported; Recommends Others Be Modified or Discontinued](https://www.globenewswire.com/news-release/2025/10/13/3165639/0/en/National-Advertising-Division-Finds-Certain-Reus-Cata-Kor-NAD-Claims-Supported-Recommends-Others-Be-Modified-or-Discontinued.html) · GlobeNewswire Inc. · Oct 13, 2025 · neutral sentiment

## About Niagen Bioscience, Inc. Common Stock

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | MEDICINAL CHEMICALS & BOTANICAL PRODUCTS |
| Employees | 117 |
| Listed | Jun 24, 2008 |

[Company website](https://www.niagenbioscience.com)

## FAQ

### What is the Niagen Bioscience, Inc. Common Stock (NAGE) stock price today?

Niagen Bioscience, Inc. Common Stock (NAGE) is trading at $2.04 (+1.49% on the day) as of 6:54:53 PM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Niagen Bioscience, Inc. Common Stock?

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

### What is the short interest in NAGE?

As of Oct 30, 2026, NAGE has 4.35M shares short and 8.9 days to cover.

### What exchange is NAGE listed on?

Niagen Bioscience, Inc. Common Stock (NAGE) trades on Nasdaq in USD, in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry.

## Live data

Prices here are 15-minute delayed. For real-time NAGE quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=NAGE`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Niagen Bioscience, Inc. Common Stock (NAGE) insider trading](https://massive.com/quote/nage/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
